Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes
Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs w...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tamargo, Juan [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet - Fabersani, Emanuel ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:233 ; year:2017 ; day:15 ; month:04 ; pages:1-11 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ijcard.2016.11.124 |
|---|
| Katalog-ID: |
ELV014911051 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV014911051 | ||
| 003 | DE-627 | ||
| 005 | 20230625114222.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijcard.2016.11.124 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017005000026.pica |
| 035 | |a (DE-627)ELV014911051 | ||
| 035 | |a (ELSEVIER)S0167-5273(16)33583-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 630 |a 640 |a 610 |q VZ |
| 100 | 1 | |a Tamargo, Juan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. | ||
| 520 | |a Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. | ||
| 700 | 1 | |a Rosano, Giuseppe M.C. |4 oth | |
| 700 | 1 | |a Delpón, Eva |4 oth | |
| 700 | 1 | |a Ruilope, Luis |4 oth | |
| 700 | 1 | |a López-Sendón, Jose |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Fabersani, Emanuel ELSEVIER |t Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000849189 |
| 773 | 1 | 8 | |g volume:233 |g year:2017 |g day:15 |g month:04 |g pages:1-11 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijcard.2016.11.124 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 233 |j 2017 |b 15 |c 0415 |h 1-11 |g 11 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
j t jt |
|---|---|
| matchkey_str |
tamargojuanrosanogiuseppemcdelpnevaruilo:2017----:hraooiaraoshtaepanhrnoieciiatilhvfiei |
| hierarchy_sort_str |
2017transfer abstract |
| publishDate |
2017 |
| allfields |
10.1016/j.ijcard.2016.11.124 doi GBVA2017005000026.pica (DE-627)ELV014911051 (ELSEVIER)S0167-5273(16)33583-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 610 VZ Tamargo, Juan verfasserin aut Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. Rosano, Giuseppe M.C. oth Delpón, Eva oth Ruilope, Luis oth López-Sendón, Jose oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:233 year:2017 day:15 month:04 pages:1-11 extent:11 https://doi.org/10.1016/j.ijcard.2016.11.124 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 233 2017 15 0415 1-11 11 045F 610 |
| spelling |
10.1016/j.ijcard.2016.11.124 doi GBVA2017005000026.pica (DE-627)ELV014911051 (ELSEVIER)S0167-5273(16)33583-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 610 VZ Tamargo, Juan verfasserin aut Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. Rosano, Giuseppe M.C. oth Delpón, Eva oth Ruilope, Luis oth López-Sendón, Jose oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:233 year:2017 day:15 month:04 pages:1-11 extent:11 https://doi.org/10.1016/j.ijcard.2016.11.124 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 233 2017 15 0415 1-11 11 045F 610 |
| allfields_unstemmed |
10.1016/j.ijcard.2016.11.124 doi GBVA2017005000026.pica (DE-627)ELV014911051 (ELSEVIER)S0167-5273(16)33583-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 610 VZ Tamargo, Juan verfasserin aut Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. Rosano, Giuseppe M.C. oth Delpón, Eva oth Ruilope, Luis oth López-Sendón, Jose oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:233 year:2017 day:15 month:04 pages:1-11 extent:11 https://doi.org/10.1016/j.ijcard.2016.11.124 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 233 2017 15 0415 1-11 11 045F 610 |
| allfieldsGer |
10.1016/j.ijcard.2016.11.124 doi GBVA2017005000026.pica (DE-627)ELV014911051 (ELSEVIER)S0167-5273(16)33583-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 610 VZ Tamargo, Juan verfasserin aut Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. Rosano, Giuseppe M.C. oth Delpón, Eva oth Ruilope, Luis oth López-Sendón, Jose oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:233 year:2017 day:15 month:04 pages:1-11 extent:11 https://doi.org/10.1016/j.ijcard.2016.11.124 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 233 2017 15 0415 1-11 11 045F 610 |
| allfieldsSound |
10.1016/j.ijcard.2016.11.124 doi GBVA2017005000026.pica (DE-627)ELV014911051 (ELSEVIER)S0167-5273(16)33583-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 610 VZ Tamargo, Juan verfasserin aut Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. Rosano, Giuseppe M.C. oth Delpón, Eva oth Ruilope, Luis oth López-Sendón, Jose oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:233 year:2017 day:15 month:04 pages:1-11 extent:11 https://doi.org/10.1016/j.ijcard.2016.11.124 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 233 2017 15 0415 1-11 11 045F 610 |
| language |
English |
| source |
Enthalten in Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet Amsterdam [u.a.] volume:233 year:2017 day:15 month:04 pages:1-11 extent:11 |
| sourceStr |
Enthalten in Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet Amsterdam [u.a.] volume:233 year:2017 day:15 month:04 pages:1-11 extent:11 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| authorswithroles_txt_mv |
Tamargo, Juan @@aut@@ Rosano, Giuseppe M.C. @@oth@@ Delpón, Eva @@oth@@ Ruilope, Luis @@oth@@ López-Sendón, Jose @@oth@@ |
| publishDateDaySort_date |
2017-01-15T00:00:00Z |
| hierarchy_top_id |
ELV000849189 |
| dewey-sort |
3610 |
| id |
ELV014911051 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV014911051</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625114222.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijcard.2016.11.124</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017005000026.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV014911051</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-5273(16)33583-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tamargo, Juan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rosano, Giuseppe M.C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Delpón, Eva</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ruilope, Luis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">López-Sendón, Jose</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Fabersani, Emanuel ELSEVIER</subfield><subfield code="t">Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000849189</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:233</subfield><subfield code="g">year:2017</subfield><subfield code="g">day:15</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:1-11</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijcard.2016.11.124</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">233</subfield><subfield code="j">2017</subfield><subfield code="b">15</subfield><subfield code="c">0415</subfield><subfield code="h">1-11</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Tamargo, Juan |
| spellingShingle |
Tamargo, Juan ddc 610 ddc 630 Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes |
| authorStr |
Tamargo, Juan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000849189 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 630 - Agriculture & related technologies 640 - Home & family management |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 630 640 610 VZ Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes |
| topic |
ddc 610 ddc 630 |
| topic_unstemmed |
ddc 610 ddc 630 |
| topic_browse |
ddc 610 ddc 630 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
g m r gm gmr e d ed l r lr j l s jls |
| hierarchy_parent_title |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| hierarchy_parent_id |
ELV000849189 |
| dewey-tens |
610 - Medicine & health 630 - Agriculture 640 - Home & family management |
| hierarchy_top_title |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000849189 |
| title |
Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes |
| ctrlnum |
(DE-627)ELV014911051 (ELSEVIER)S0167-5273(16)33583-5 |
| title_full |
Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes |
| author_sort |
Tamargo, Juan |
| journal |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| journalStr |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
1 |
| author_browse |
Tamargo, Juan |
| container_volume |
233 |
| physical |
11 |
| class |
610 610 DE-600 630 640 610 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tamargo, Juan |
| doi_str_mv |
10.1016/j.ijcard.2016.11.124 |
| dewey-full |
610 630 640 |
| title_sort |
pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes |
| title_auth |
Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes |
| abstract |
Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. |
| abstractGer |
Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. |
| abstract_unstemmed |
Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes |
| url |
https://doi.org/10.1016/j.ijcard.2016.11.124 |
| remote_bool |
true |
| author2 |
Rosano, Giuseppe M.C. Delpón, Eva Ruilope, Luis López-Sendón, Jose |
| author2Str |
Rosano, Giuseppe M.C. Delpón, Eva Ruilope, Luis López-Sendón, Jose |
| ppnlink |
ELV000849189 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.ijcard.2016.11.124 |
| up_date |
2024-07-06T22:47:48.446Z |
| _version_ |
1803871656027881472 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV014911051</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625114222.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijcard.2016.11.124</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017005000026.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV014911051</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-5273(16)33583-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tamargo, Juan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Acute heart failure (AHF) represents a clinical challenge as it encloses a heterogeneous group of syndromes (AHFS) with different pathophysiology, clinical presentations, prognosis and response to therapy. In the last 25years multiple therapeutic targets have been identified and numerous new drugs were evaluated but, up to now, all failed to demonstrate a consistent benefit on clinical outcomes. Moreover, a repeated finding has been the poor correlation between the encouraging results of preclinical and early clinical trials and the lack of effect on outcomes observed in phase III trials. We review several possible pharmacological reasons that may explain the lack of success to develop new drugs and the pharmacological challenges to overcome in the future to develop new more effective and safer drugs for the treatment of AHFS.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rosano, Giuseppe M.C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Delpón, Eva</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ruilope, Luis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">López-Sendón, Jose</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Fabersani, Emanuel ELSEVIER</subfield><subfield code="t">Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000849189</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:233</subfield><subfield code="g">year:2017</subfield><subfield code="g">day:15</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:1-11</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijcard.2016.11.124</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">233</subfield><subfield code="j">2017</subfield><subfield code="b">15</subfield><subfield code="c">0415</subfield><subfield code="h">1-11</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4000645 |